IL2 and metastatic melanoma: Some research on fusion proteins of antibody and IL-2 as a payload demonstrated strong anti-cancer activity in various mouse models of cancer, including metastatic melanoma, neuroblastoma, prostate carcinoma, colon adenocarcinoma, non-small cell lung carcinoma, and lymphoma.